True or false: Nivolumab improved overall survival versus gemcitabine/pegylated liposomal doxorubicin in platinum-resistant ovarian cancer.
Quiz: Is Significant Clinical Benefit Derived From Maintenance Olaparib for BRCA-Mutated Ovarian Cancer?
True or false: Long-term olaparib maintenance significantly extended PFS over placebo in BRCA-mutated ovarian cancer.
Nivolumab did not improve survival versus gemcitabine and pegylated liposomal doxorubicin (GEM/PLD) in platinum-resistant ovarian cancer in the phase 3 NINJA trial.
Patients with BRCA-mutated ovarian cancer given maintenance olaparib after first-line platinum-based chemotherapy had extended rates of PFS and RFS, according to findings from the SOLO1 trial.
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
Focusing on patient-centered outcomes from the ARIEL3 trial, rucaparib extended PFS in the maintenance setting for ovarian cancer despite toxicities.
True or False: Endometriosis-associated ovarian cancer often occurs within 36 months of follow-up for endometrial cysts, leading experts to suggest that cancer cells may already be present in…
Tumor-specific TP53 variants were detected in Papanicolaou tests for routine cervical cancer screenings up to 6 years before ovarian cancer diagnosis.